A randomized, open-label study of the effect of MabThera, with and without fludarabine/cyclophosphamide, on progression-free survival in patients with chronic lymphocytic leukemia.
Phase of Trial: Phase III
Latest Information Update: 01 Oct 2016
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Fludarabine
- Indications Chronic lymphocytic leukaemia
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Sponsors Roche
- 29 Aug 2016 Results (n=554) of this and other trial (CLL10) published in the Journal of Clinical Oncology (2016).
- 08 Dec 2015 Results (pooled analysis of CLL8 and CLL10 studies) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (n = 635).
- 20 Oct 2015 Updated long term follow-up results published in the Blood
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History